dc.contributor.author | Nowakowski, GS | |
dc.contributor.author | Willenbacher, W | |
dc.contributor.author | Greil, R | |
dc.contributor.author | Larsen, TS | |
dc.contributor.author | Patel, K | |
dc.contributor.author | Jäger, U | |
dc.contributor.author | Manges, RF | |
dc.contributor.author | Trümper, L | |
dc.contributor.author | Everaus, H | |
dc.contributor.author | Kalakonda, N | |
dc.contributor.author | Brown, P | |
dc.contributor.author | Jørgensen, JM | |
dc.contributor.author | Cunningham, D | |
dc.contributor.author | Dell'Aringa, J | |
dc.contributor.author | Fox, B | |
dc.contributor.author | Rubio, ND | |
dc.contributor.author | Kilavuz, N | |
dc.contributor.author | Casadebaig, M-L | |
dc.contributor.author | Manzke, O | |
dc.contributor.author | Munoz, J | |
dc.date.accessioned | 2022-02-11T09:53:51Z | |
dc.date.available | 2022-02-11T09:53:51Z | |
dc.date.issued | 2021-11-19 | |
dc.identifier.citation | International journal of hematology, 2021 | en_US |
dc.identifier.issn | 0925-5710 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5009 | |
dc.identifier.eissn | 1865-3774 | en_US |
dc.identifier.eissn | 1865-3774 | |
dc.identifier.doi | 10.1007/s12185-021-03241-4 | en_US |
dc.identifier.doi | 10.1007/s12185-021-03241-4 | |
dc.description.abstract | Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP). Evidence shows chemotherapy and immune checkpoint blockade can increase antitumor efficacy. This study investigated durvalumab, a programmed death-ligand 1 inhibitor, combined with R-CHOP or lenalidomide + R-CHOP (R<sup>2</sup>-CHOP) in newly diagnosed high-risk DLBCL. Patients received durvalumab 1125 mg every 21 days for 2-8 cycles + R-CHOP (non-activated B-cell [ABC] subtype) or R<sup>2</sup>-CHOP (ABC), then durvalumab consolidation (1500 mg every 28 days). Of 46 patients, 43 received R-CHOP and three R<sup>2</sup>-CHOP. All patients had the high-risk disease; 14 (30.4%) and eight (17.4%) had double- or triple-hit DLBCL, respectively. Following induction, 20/37 (54.1%) patients receiving durvalumab + R-CHOP achieved complete response (CR), and seven (18.9%) partial response (PR); 25 (67.6% [95% CI 50.2-82.0]) continued to consolidation and were progression-free at 12 months. Among efficacy-evaluable patients with double- or triple-hit DLBCL (n = 12), five achieved CR and five PR. Adverse events were generally consistent with R-CHOP. Correlative analyses did not identify conclusive biomarkers of response. Durvalumab + R-CHOP is feasible in DLBCL with no new safety signals, but the combination provided no greater benefit than R-CHOP. | en_US |
dc.format | Print-Electronic | en_US |
dc.language | eng | en_US |
dc.language.iso | eng | en_US |
dc.rights.uri | http://www.rioxx.net/licenses/all-rights-reserved | en_US |
dc.title | Safety and efficacy of durvalumab with R-CHOP or R<sup>2</sup>-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-10-17 | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1007/s12185-021-03241-4 | en_US |
rioxxterms.licenseref.startdate | 2021-11-19 | |
dc.relation.isPartOf | International journal of hematology | en_US |
pubs.notes | Not known | en_US |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | en_US |
pubs.embargo.terms | Not known | en_US |
icr.researchteam | Medicine (RMH Smith Cunningham) | |
dc.contributor.icrauthor | Cunningham, David | |